ALSO NOTED: Paxil back on the market; Tarceva gets European recommendation; and much more...

> GlaxoSmithKline has returned Paxil CR to the market, three months after regulators found manufacturing problems at three of its facilities. Story

> A European drug panel has recommended Roche's Tarceva for lung cancer. Story

> The European Medicines Agency has recommended the continued suspension of Pfizer's Bextra with new warnings regarding all Cox-2 inhibitors. Story

> Neurobiological Technologies has signed a manufacturing deal with Baxter and Nordmark for a Phase III trial of Viprinex. Release

> Switzerland's Debiopharm and Neovacs have signed an equity and licensing deal for the development of Neovacs' anti-TNF-Alpha product. Release

> The EU's Committee for Medicinal Products for Human Use has recommended approval of Schering's contrast agent, Vasovist. Article

And Finally... Even as pharmaceutical drugs continue their double-digit rise in prices, generic drug prices are remaining steady. Story

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.